Pages that link to "Q30887373"
Jump to navigation
Jump to search
The following pages link to Immunotherapy for advanced renal cell cancer. (Q30887373):
Displaying 50 items.
- Immunotherapy for metastatic renal cell carcinoma (Q24186688) (← links)
- Axitinib for the Management of Metastatic Renal Cell Carcinoma (Q24613720) (← links)
- Immunotherapy for Bone and Soft Tissue Sarcomas (Q28088363) (← links)
- Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib (Q28765488) (← links)
- Immunotherapy for metastatic renal cell carcinoma (Q30234458) (← links)
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials (Q34032864) (← links)
- Role of surgery in advanced/metastatic renal cell carcinoma (Q34123980) (← links)
- The current status of interferon-alpha treatment in advanced renal cancer (Q34249614) (← links)
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (Q34586436) (← links)
- Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies (Q34627828) (← links)
- Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. (Q35205445) (← links)
- Prognostic factors of immunotherapy in metastatic renal cell carcinoma (Q35625635) (← links)
- What should urologists know about evidence-based medicine? (Q35686419) (← links)
- A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer (Q35757233) (← links)
- Allogeneic stem-cell transplantation for renal-cell cancer. (Q35874715) (← links)
- Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index (Q35906196) (← links)
- Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment? (Q36026873) (← links)
- Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents (Q36045973) (← links)
- Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer (Q36352105) (← links)
- Cytokine therapy: a standard of care for metastatic renal cell carcinoma? (Q36373462) (← links)
- Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma (Q36710382) (← links)
- Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. (Q36713471) (← links)
- Recent advances in the therapy of renal cancer (Q36717355) (← links)
- Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma (Q36752747) (← links)
- The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat (Q36966415) (← links)
- Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors (Q37132720) (← links)
- Immunotherapy for renal cell cancer in the era of targeted therapy (Q37183451) (← links)
- Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. (Q37187448) (← links)
- The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations (Q37372797) (← links)
- UK guidelines for the systemic treatment of renal cell carcinoma. (Q37487540) (← links)
- Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer. (Q37522583) (← links)
- Metastatic renal cell carcinoma management (Q37524516) (← links)
- What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic renal cell carcinoma? (Q37627804) (← links)
- Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach (Q37768461) (← links)
- Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors (Q37771904) (← links)
- Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action (Q37866796) (← links)
- Second-line therapy for refractory renal-cell carcinoma. (Q37938160) (← links)
- Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). (Q38013775) (← links)
- Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma (Q38110934) (← links)
- Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art (Q38264616) (← links)
- Pharmacotherapies for renal cell carcinoma in Japan (Q38668274) (← links)
- Immunotherapy for genitourinary cancer: state of the art and new perspectives. (Q38835246) (← links)
- Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study (Q40485362) (← links)
- Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. (Q41895084) (← links)
- Systemic therapy of renal cell carcinoma (Q42791098) (← links)
- A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. (Q42975802) (← links)
- How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma (Q43012853) (← links)
- The prognostic value of erythrocyte polyamines in the preoperative evaluation of patients with renal cell carcinoma (Q43119778) (← links)
- Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme (Q43550717) (← links)
- Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study (Q45090159) (← links)